<DOC>
	<DOC>NCT00478855</DOC>
	<brief_summary>1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection. 2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.</brief_summary>
	<brief_title>Tazocin Intervention Study</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>All patients admitted or transferred to the ICU/pulmonary/Infection units Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>